Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids

Recent studies have shown that administering the aromatase inhibitor exemestane after 2–3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment. Although many of the adverse ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Francini, G, Petrioli, R, Montagnani, A, Cadirni, A, Campagna, S, Francini, E, Gonnelli, S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360614/
https://www.ncbi.nlm.nih.gov/pubmed/16835585
http://dx.doi.org/10.1038/sj.bjc.6603258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360614/
https://www.ncbi.nlm.nih.gov/pubmed/16835585
http://dx.doi.org/10.1038/sj.bjc.6603258

Ejemplares similares